Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexMale
• Healthy volunteersNo

You may be able to join if

• Patient must have histologically or cytologically documented evidence of prostate adenocarcinoma
• Patient must previously have undergone radical prostatectomy
• Patient must previously have undergone either adjuvant or salvage radiation therapy to the prostatic fossa +/- whole pelvis
• Patient must have a prostate specific antigen (PSA) >= 0.2 and < 10 ng/mL. If there is only one PSA value that has risen to >= 0.2 with this biochemical recurrence, a second PSA value must be confirmed to be within >= 0.2 and < 10 ng/mL at least 2 weeks from the first value and within 28 days of enrollment
• PSA doubling time must be calculated utilizing either all PSA measurements > 0.1 ng/mL from most recent biochemically-recurred (BCR) or the most recent 3 PSA measurements > 0.1 ng/mL (if the latter, all 3 PSA measurements must be > 2 weeks apart to be used in the calculation). PSA doubling time must be > 3 months and < 18 months. The Memorial Sloan Kettering PSA doubling time calculator should be used
• Patient must have no previous evidence of radiographically detectable metastatic prostate cancer by conventional CT and bone scan imaging
• Patient must have total testosterone level > 120 ng/dL demonstrated within 42 days of enrollment
• Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Absolute neutrophil count (ANC) >= 1.0 X 10^9/L
• Platelet count >= 100 X 10^9/L
• Hemoglobin >= 9 g/dL
• Potassium >= 3.5
• Serum bilirubin =< 1.5 X upper limit of normal (ULN) or =< 3 X ULN for patients with documented Gilbert's syndrome
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 X ULN
• Creatinine clearance (Cr Cl) >= 30 mL/min as estimated by the Cockcroft-Gault criteria or as determined by 24 hour Cr Cl measurement
• Patient must be >= 18 years of age on day of signing informed consent
• Patient must be able to understand and authorize informed consent

You cannot join if

• Chronic active hepatitis B or C
• History of a second, non-prostate malignancy that required systemic therapy in the last 2 years except cancer in situ of bladder and non-melanomatous cancers of the skin
• Patient with a serious underlying medical condition that would otherwise impair the patient's ability to undergo fluciclovine or PSMA PET/CT imaging or receive subsequent treatment
• Any condition that would alter the patient's mental status, prohibiting understanding and/or authorization of informed consent
• Expected lifespan of less than 12 weeks
• Inability to lay still for imaging
• Weight > 300 lbs. (due to equipment specifications)
• Any other underlying medical condition that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and/or follow up

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

abiraterone acetate. An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels. NCI Drug Dictionary

Treatments listed in the registry

• Positron Emission Tomography (Procedure): Undergo fluciclovine PET/CT
• Lymphadenectomy (Procedure): Undergo lymphadenectomy
• Radiation Therapy (Radiation): Undergo radiation therapy
• Abiraterone Acetate (Drug): Given PO
• Prednisone (Drug): Given PO
• Computed Tomography (Procedure): Undergo fluciclovine PET/CT
• Abiraterone (Drug): Given PO
• PSMA PET Scan (Procedure): Undergo PSMA PET scan

Non Randomized · Parallel · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• CT scans: Part of the study plan
• PET scans: Part of the study plan
• surgery: Part of the study plan
• radiation: Part of the study plan

Main goals

• Undetectable PSA (< 0.2 ng/mL) rate (At 2 years)

Other goals

• Total testosterone
• Median time to reinitiation of antiandrogen therapy (ADT)
• Overall survival
• Number of patients with abnormalities within the prostatic fossa with PSA < 10 ng/mL
• Number of patients without abnormalities with PSA < 10 ng/mL
• Number of patients with PSA < 10 mg/mL and > 3 regions of metastatic prostate cancer on fluciclovine PET/CT

Planned enrollment: 100 (estimated).

• University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
• Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT04175431
• NCI Drug Dictionary: C68845

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Jul 6, 2026. Public record; not medical advice.